Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Other Non-Current Assets (2016 - 2025)

Gsk has reported Other Non-Current Assets over the past 10 years, most recently at $2.9 billion for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.9 billion for Q4 2025, up 14.63% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (up 14.63% YoY), and the annual figure for FY2025 was $2.9 billion, up 14.63%.
  • Other Non-Current Assets for Q4 2025 was $2.9 billion at Gsk, up from $2.5 billion in the prior quarter.
  • Over the last five years, Other Non-Current Assets for GLAXF hit a ceiling of $2.9 billion in Q4 2025 and a floor of $1.4 billion in Q4 2022.
  • Median Other Non-Current Assets over the past 5 years was $2.3 billion (2021), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Other Non-Current Assets: surged 64.36% in 2021 and later tumbled 38.01% in 2022.
  • Gsk's Other Non-Current Assets stood at $2.3 billion in 2021, then tumbled by 38.01% to $1.4 billion in 2022, then soared by 40.38% to $2.0 billion in 2023, then increased by 26.78% to $2.5 billion in 2024, then rose by 14.63% to $2.9 billion in 2025.
  • The last three reported values for Other Non-Current Assets were $2.9 billion (Q4 2025), $2.5 billion (Q4 2024), and $2.0 billion (Q4 2023) per Business Quant data.